Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152591 · ClinicalTrials.gov registry record · Phase 2
Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT03152591 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT03152591, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.
Interventions
- DRUG Placebo
- DRUG LIK066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152591
The ClinicalTrials.gov registry entry for NCT03152591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03152591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152591 about?
NCT03152591 is a clinical study titled "Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome". The purpose of the study was to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women.
What is the current status of trial NCT03152591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-07-24. Estimated completion is 2018-06-25.
What interventions are being tested in trial NCT03152591?
The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT03152591?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.